APR 20, 2015 09:53 AM PDT

Brain Tumors May be New Victims of Ebola-like Virus

Brain tumors are notoriously difficult for most drugs to reach, but Yale researchers have found a promising but unlikely new ally against brain cancers - portions of a deadly virus similar to Ebola.
Glioma tumor cells (in red) and being destroyed in a rat brain by a chimeric virus (green) containing elements of the Lassa virus, an ebola-like pathogen.
A virus containing proteins found in the Lassa virus - like Ebola, a hemorrhagic fever virus found in some parts of Africa - not only passed through the formidable blood-brain barrier but destroyed brain tumors in mice, according to research released April 16 in the Journal of Virology.

"The chimeric virus turned out to be completely safe in animals and tended to specifically target cancer cells in the brain," said Tony van den Pol, professor of neurosurgery at the Yale School of Medicine, researcher at the Yale Cancer Center and senior author of the study.

Researchers have long been intrigued by the VSV virus, a relative of rabies, which can pass through membranes that protect the brain to infect brain tumors. The unaltered virus, however, can cause serious neurological damage. The Yale team wanted to know if portions of VSV together with portions of unrelated viruses might be safely used to attack brain tumors in mice. Some of the viruses tested, like the altered virus that contained Ebola genes, did reach the brain tumor, but did not effectively attack brain tumors. The altered Lassa virus, however, safely and effectively targeted and destroyed cancer cells within the brain. The Lassa chimeric virus targeted both gliomas and melanoma, another type of cancer that can migrate into the brain.

"We are very excited about these new chimeric viruses that contain genes from multiple viruses. They work well in targeting cancer in animals, and we hope that they will also work effectively if tested in humans," said van den Pol.

Guido Wollmann, Eugene Drokhlyansky, and Connie Cepko are other authors of the paper.

The work was funded by the NIH National Cancer Institute.

Source: Yale
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
OCT 18, 2019
Cancer
OCT 18, 2019
Combining Breast and Lung Cancer Drugs to Overcome Treatment Resistance
The efforts to overcome cancer’s ability to evolve and resist treatment take many forms and comprise a vital and active branch of contemporary cancer...
OCT 18, 2019
Drug Discovery & Development
OCT 18, 2019
Anti-cancer Drug Disguises as Fat
According to a study published in the Journal of the American Chemical Society (JACS), a new drug-delivery system disguises as fat in order to outsmart tum...
OCT 18, 2019
Cancer
OCT 18, 2019
The role of sleeper cells in metastasis
New research published in the journal Nature Communications aims to explain why some breast cancers recur following cancer treatment. According to col...
OCT 18, 2019
Cell & Molecular Biology
OCT 18, 2019
Stem Cell Derived Natural Killer T Cells as Novel and Long-term Cancer Treatment
Hematopoietic stem cells are used to create a population of Natural Killer T-cells that could sustain and renew within the immune system, and attack cancer cells....
OCT 18, 2019
Drug Discovery & Development
OCT 18, 2019
How does a drug for colorectal cancer work?
Colorectal cancer is a fatal and common disease, and treatment decisions are often based on what genes have been mutated in the development of the cancer. ...
OCT 18, 2019
Cancer
OCT 18, 2019
New diagnostic tool for thyroid cancer
Thyroid cancer diagnoses have risen in the last thirty years from 6 per 100,000 to more than 14 per 100,000. That’s according to the Surveillance, Ep...
Loading Comments...